Clinical Podcasts

UpToDate faculty discuss important “What’s New” and “Practice Changing UpDates”, based on recent medical journal articles, in our clinical podcasts. Our contributors are recognized physician leaders in their fields and offer their expertise regarding each update and its impact on clinical practice. Each clinical podcast includes the most current clinical information available as of the release date listed.

Support for UpToDate Talk is provided by UpToDate, Wolters Kluwer. UpToDate is entirely funded by the subscriptions of its users and does not accept advertising or funding unrelated to subscriptions. The opinions in such podcasts are entirely those of the discussants, and these discussants are authors and editors for UpToDate. View the UpToDate conflict of interest policy.

To be alerted as each new episode airs, simply subscribe to our podcast channel on iTunes. Also, check out our Healthcare Industry Podcasts that explore healthcare initiatives with an impact on quality and patient safety. We hope you will find these series an enjoyable way to keep UpToDate!

Revised follow-up for solitary pulmonary nodule; Safe sleep practices and SIDS

Date Released: Sep 20 2017

This podcast features Dr. Steven Weinberger, discussing new guidelines on the management of solitary pulmonary nodules, and Dr. Michael Corwin, discussing interventions to promote safe sleep practices for infants and decrease the incidence of sudden infant death syndrome (SIDS). Dr. Nancy Sokol hosts.

Dr. WeinbergerDr. Steven Weinberger is an Adjunct Professor of Medicine at the University of Pennsylvania School of Medicine.
Dr. CorwinDr. Michael Corwin is Associate Professor of Pediatrics and Epidemiology at the Boston University Schools of Medicine and Public Health.

Segment on solitary pulmonary nodule (Dr. Weinberger):

  1. MacMahon H, Naidich DP, Goo JM, et al. Guidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the Fleischner Society 2017. Radiology 2017; 284:228.

Segment on SIDS prevention (Dr. Corwin):

  1. Doering JJ, Salm Ward TC. The Interface Among Poverty, Air Mattress Industry Trends, Policy, and Infant Safety. Am J Public Health 2017; 107:945.
  2. Moon RY. Air Mattresses Are Not Appropriate Sleep Spaces for Infants. Am J Public Health 2017; 107:838.

Steven E Weinberger, MD Nothing to disclose

Michael J Corwin, MD Nothing to disclose

Sentinel lymph node metastasis in melanoma; Transcranial electrical stimulation for depression

Date Released: Sep 6 2017

This episode features Dr. Michael Atkins, discussing the management of positive sentinel lymph nodes in patients with cutaneous melanoma, and Dr. Peter Roy-Byrne, discussing an investigational transcranial therapy for individuals with depression. Dr. April Eichler hosts.

Dr. AtkinsDr. Michael Atkins is Scholl Professor and Vice Chair of Medical Oncology at Georgetown University Medical Center and Deputy Director of the Georgetown Lombardi Comprehensive Cancer Center in Washington, D.C.
Dr. Roy-ByrneDr. Peter Roy-Byrne is Professor Emeritus in the Department of Psychiatry and Behavioral Sciences at the University of Washington School of Medicine in Seattle.

Segment on management of a positive sentinel lymph node biopsy in patients with cutaneous melanoma (Dr. Michael Atkins):

  1. Faries MB, Thompson JF, Cochran AJ, et al. Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. N Engl J Med 2017; 376:2211.

Segment on transcranial direct current stimulation for depression (Dr. Peter Roy-Byrne):

  1. Brunoni AR, Moffa AH, Sampaio-Junior B, et al. Trial of Electrical Direct-Current Therapy versus Escitalopram for Depression. N Engl J Med 2017; 376:2523.

Michael B Atkins, MD Consultant/Advisory Boards: BMS; Merck; Novartis; Pfizer; Roche; Exelixis; Eisai [Melanoma; RCC; immunotherapy (Everoliumus, pazopanib; dabrafenib/trametinib; axitinib, sunitinib, avelumab; vemurafenib/cobimetinib, atezolizumab; ipilimumab/nivolumab; pembrolizumab, interferon; cabozantinib; lenvatinib)].

Peter P Roy-Byrne, MD Employment: Mass Medical Society (journal Watch); Wiley Lliss (Depression and Anxiety) [Editor in Chief]. Stock Options: Valant Medical Solutions [behavioral health (EMR)].

Pediatric behavior & celiac autoimmunity; Adjuvant capecitabine & HER2-negative breast cancer

Date Released: Aug 23 2017

In this episode, Dr. Ivor Hill discusses the psychological impact of celiac autoimmunity in children, and Dr. Daniel Hayes discusses adjuvant therapy with capecitabine for selected women with breast cancer.

Dr. HillDr. Ivor Hill is is Professor of Clinical Pediatrics at Ohio State University College of Medicine and Medical Director of the Celiac Disease Center at Nationwide Children's Hospital.
Dr. HayesDr. Daniel Hayes Professor of Medicine and the Clinical Director of the Breast Oncology Program at the University of Michigan Comprehensive Cancer Center. He is past president of the American Society of Clinical Oncology.

Segment on celiac disease autoimmunity (Dr. Ivor Hill):

  1. Smith LB, Lynch KF, Kurppa K, et al. Psychological Manifestations of Celiac Disease Autoimmunity in Young Children. Pediatrics 2017; 139.

Segment on adjuvant capecitabine (Dr. Daniel Hayes):

  1. Masuda N, Lee SJ, Ohtani S, et al. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. N Engl J Med 2017; 376:2147.

Ivor D Hill, MD Nothing to disclose

Daniel F Hayes, MD Grant/Research/Clinical Trial Support: Janssen R&D, LLC [Breast cancer (Abiraterone)]; Janssen R&D, LLC [Breast cancer (CellSearch)]; Puma Biotechnology, Inc. [Breast cancer (Neratinib)]; Pfizer [Breast cancer (Palbociclib)]; Astra Zeneca [Breast cancer (Circulating tumor cells)]; Eli Lilly and Company [Breast cancer]. Speaker's Bureau: Lilly Oncology (Breast cancer). Patent Holder: Immunicon Corporation [Inventor (05725638.0-1223-US2005008602)]; University of Michigan [Inventor (US 8,790,878 B2)]; University of Michigan [Inventor (US 8,951,484 B2)]. Equity Ownership/Stock Options: Oncimmune LLC [Stock]; Inbiomotion [Stock]. Other Financial Interest: Janssen R&D, LLC [Breast cancer (CellSearch)].

Edaravone for amyotrophic lateral sclerosis; Neonatal mortality in US planned home births

Date Released: Aug 9 2017

This episode features Dr. Jeremy Shefner, discussing the use of edaravone for the treatment of amyotrophic lateral sclerosis, and Dr. Charles Lockwood, discussing neonatal mortality in planned home births. Dr. Helen Hollingsworth hosts.

Dr. ShefnerDr. Jeremy Shefner is Professor and Chair of Neurology at the Barrow Neurological Institute, Professor of Neurology at the University of Arizona in Phoenix, and Clinical Professor of Neurology at Creighton University.
Dr. LockwoodDr. Charles Lockwood is Professor of Obstetrics and Gynecology at the University of South Florida, Dean of the Morsani College of Medicine and Senior Vice President of the University of South Florida Health.

Segment on edaravone for amyotrophic lateral sclerosis (Dr. Jeremy Shefner):

  1. Writing Group, Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2017; 16:505.

Segment on neonatal mortality in US planned home births (Dr. Charles Lockwood):

  1. Grunebaum A, McCullough LB, Sapra KJ, et al. Planned home births: The need for additional contraindications. Am J Obstet Gynecol 2017; 216:401.e1.

Jeremy M Shefner, MD, PhD Grant/Research Support: Biogen Idec; Cytokinetics; Neuraltus [ALS]; Avanir [ALS (Nuedexta)]. Consultant/Advisory Boards: Biogen Idec; Cytokinetics; Ionis; Neuraltus; Mitsubishi Tanabe [ALS]; Edaravone [ALS (MT Pharma)].

Charles J Lockwood, MD, MHCM Consultant/Advisory Boards: Celula [Aneuploidy screening (No current products or drugs in the US)].